(Q44598654)

English

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

scientific article published in October 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Wassmann B

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Scheuring U

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pfeifer H

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Binckebanck A

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Käbisch A

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Lübbert M

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Leimer L

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Gschaidmeier H

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hoelzer D

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1919-1924

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403093

0 references

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Philadelphia chromosome-positive acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Salvage therapy for refractory or relapsed acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Perspectives on the development of a molecularly targeted agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Low concentrations of STI571 in the cerebrospinal fluid: a case report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Interferon-alpha treatment of acute lymphoblastic leukemia relapse after unrelated bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

21 January 2018

Recent approaches in acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

7 January 2021

based on heuristic

inferred from DOI database lookup

Signal transduction pathways involved in BCR-ABL transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403093

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403093

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44598654&oldid=1636535341"